Syndax Pharmaceuticals (SNDX) Earnings Call Presentation

Revuforj (revumenib) - Revuforj generated $20 million in net revenue in 1Q25[3] - Syndax initiated a pivotal frontline trial of revumenib with ven/aza in mNPM1 and KMT2Ar patients unfit for intensive chemo in 1Q25[3] - Syndax completed the submission of Revuforj sNDA for R/R mNPM1 AML in April 2025[3] - In the AUGMENT-101 trial, Revuforj showed a CR+CRh rate of 212% (22/104) with a median duration of 64 months[29] - In the Phase 2 portion of AUGMENT-101, revumenib demonstrated a CR/CRh of 23% (15/64) in R/R mNPM1 AML patients[47] Niktimvo (axatilimab-csfr) - Niktimvo generated $136 million in net revenue in 1Q25 (reported by Incyte)[3] - In the AGAVE-201 trial, Niktimvo showed an overall response rate of 75% (59/79) through 6 months[78] - 60% of responders maintained a response for at least 12 months[78] Financial Position - Syndax had $6021 million in cash and cash equivalents as of March 31, 2025, expected to fund the company to profitability[3] - Syndax's total revenue for 1Q25 was $20 million[102]